Țară: Irlanda
Limbă: engleză
Sursă: HPRA (Health Products Regulatory Authority)
Atazanavir sulfate
Accord Healthcare Ireland Ltd.
J05AE08
Atazanavir sulfate
300 milligram(s)
Capsule, hard
atazanavir
Marketed
2019-06-28
1 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT ATAZANAVIR 200 MG HARD CAPSULES ATAZANAVIR 300 MG HARD CAPSULES atazanavir READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any questions, ask your doctor, pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. - The full name of this medicine is Atazanavir 200mg, 300mg hard capsules, but within this leaflet it will be referred to as Atazanavir capsules. WHAT IS IN THIS LEAFLET 1. What Atazanavir capsules are and what they are used for 2. What you need to know before you take Atazanavir capsules 3. How to take Atazanavir capsules 4. Possible side effects 5. How to store Atazanavir capsules 6. Contents of the pack and other information 1. WHAT ATAZANAVIR CAPSULES ARE AND WHAT THEY ARE USED FOR ATAZANAVIR CAPSULES ARE AN ANTIVIRAL (OR ANTIRETROVIRAL) MEDICINE. It is one of a group called protease inhibitors. These medicines control Human Immunodeficiency Virus (HIV) infection by stopping a protein that the HIV needs for its multiplication. They work by reducing the amount of HIV in your body and this in turn, strengthens your immune system. In this way Atazanavir capsules reduces the risk of developing illnesses linked to HIV infection. Atazanavir capsules may be used by adults and children 6 years of age and older. Your doctor has prescribed Atazanavir capsules for you because you are infected by the HIV that causes Acquired Immunodeficiency Syndrome (AIDS). It is normally used in combination with other anti-HIV medicines. Your doctor will discuss with you which combination of these medicines with Atazanavir capsules are best for you. 2. WHAT YOU NEED TO KNOW BE Citiți documentul complet
Health Products Regulatory Authority 11 May 2021 CRN00C62S Page 1 of 34 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Atazanavir Accord 300 mg hard capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains atazanavir sulphate corresponding to 300 mg of atazanavir. Excipient(s) with known effect: 163 mg of lactose per capsule 0.41 mg of sunset yellow FCF (E110) per capsule For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Hard capsule. Off white to pale yellow coloured granular powder filled in hard gelatin capsules of approx. 23.5 mm in length with orange opaque cap imprinted with "H" in black colour and green opaque body imprinted with "A8" in black colour. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Atazanavir Accord capsules, co-administered with low dose ritonavir, are indicated for the treatment of HIV‑1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products (see section 4.2). Based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors (≥ 4 PI mutations). The choice of Atazanavir Accord in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patient's treatment history (see sections 4.4 and 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Therapy should be initiated by a physician experienced in the management of HIV infection. Posology _Adults_ The recommended dose of Atazanavir Accord capsules is 300 mg once daily taken with ritonavir 100 mg once daily and with food. Ritonavir is used as a booster of atazanavir pharmacokinetics (see sections 4.5 and 5.1). (See also section 4.4 Withdrawal of ritonavir only under restrictive conditions). _Paediatric patients (6 years to less than 18 years of age and weighing at least 15 kg)_ The dose of atazanavir capsules for paediatric patients is based on body weight as shown Citiți documentul complet